Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Thrombus-related focal in-stent restenosis after everolimus-eluting stent implantation.

Hayashi T, Kotani J, Ishibashi-Ueda H, Yasuda S.

Heart Vessels. 2014 Mar;29(2):273-7. doi: 10.1007/s00380-013-0350-1. Epub 2013 Apr 18.

PMID:
23595778
2.

Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.

Almalla M, Schröder J, Pross V, Marx N, Hoffmann R.

Catheter Cardiovasc Interv. 2014 May 1;83(6):881-7. doi: 10.1002/ccd.25072. Epub 2013 Jul 3.

PMID:
23765557
3.

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.

Teeuwen K, Adriaenssens T, Van den Branden BJ, Henriques JP, Van der Schaaf RJ, Koolen JJ, Vermeersch PH, Bosschaert MA, Tijssen JG, Suttorp MJ.

Trials. 2012 Dec 15;13:240. doi: 10.1186/1745-6215-13-240.

4.

Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography.

Choi HH, Kim JS, Yoon DH, Hong KS, Kim TH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK.

Int J Cardiovasc Imaging. 2012 Mar;28(3):491-7. doi: 10.1007/s10554-011-9849-7. Epub 2011 Mar 26.

PMID:
21442265
5.

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.

6.

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.

JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.

7.

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators.

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.

8.

Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.

Almalla M, Pross V, Marx N, Hoffmann R.

Coron Artery Dis. 2012 Nov;23(7):492-6.

PMID:
22990414
9.

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial.

Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, Villeneuve H, Boute E, Stauffer JC, Goy JJ, Cook S.

Trials. 2014 Jan 7;15:9. doi: 10.1186/1745-6215-15-9.

10.

Optical coherence tomography findings in lesions after sirolimus-eluting stent implantation with peri-stent contrast staining.

Tada T, Kadota K, Hosogi S, Kubo S, Ozaki M, Yoshino M, Miyake K, Eguchi H, Ohashi N, Hayakawa Y, Saito N, Otsuru S, Hasegawa D, Shigemoto Y, Habara S, Imai M, Tanaka H, Fuku Y, Oka N, Kato H, Yamamoto H, Fujii S, Goto T, Mitsudo K.

Circ Cardiovasc Interv. 2012 Oct;5(5):649-56. doi: 10.1161/CIRCINTERVENTIONS.112.968487. Epub 2012 Sep 25.

11.

Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.

Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW.

JACC Cardiovasc Interv. 2013 Oct;6(10):999-1009. doi: 10.1016/j.jcin.2013.05.017.

12.

Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.

Adriaenssens T, Dens J, Ughi G, Coosemans M, Onsea K, Dubois C, Sinnaeve P, Vrolix M, Desmet W.

EuroIntervention. 2011 May;7 Suppl K:K100-5. doi: 10.4244/EIJV7SKA17.

PMID:
22027717
13.

5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.

JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.

15.

Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.

Loh JP, Stella PR, Sangiorgi G, Silber S, Stahnke S, von Strandmann RP, Torguson R, Waksman R.

Cardiovasc Revasc Med. 2014 Jan;15(1):23-8. doi: 10.1016/j.carrev.2013.08.011.

PMID:
24444473
16.

Right coronary artery 'diverticulosis' 4 years after sirolimus-eluting stent implantation associated with very late stent thrombosis.

Good RI, Kalra S, Lee TC.

Heart. 2013 Nov;99(21):1627. doi: 10.1136/heartjnl-2013-304263. Epub 2013 Jun 7. No abstract available.

PMID:
23749781
17.

Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation.

Kim JS, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK.

Int J Cardiovasc Imaging. 2012 Aug;28(6):1281-7. doi: 10.1007/s10554-011-9943-x. Epub 2011 Aug 21.

PMID:
21858655
18.

Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial.

Antonsen L, Maeng M, Thayssen P, Christiansen EH, Hansen KN, Kaltoft A, Hansen HS, Thuesen L, Lassen JF, Jensen LO.

Catheter Cardiovasc Interv. 2014 May 1;83(6):864-72. doi: 10.1002/ccd.25180. Epub 2013 Sep 30.

PMID:
23996918
20.

Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.

Fujino Y, Attizzani GF, Bezerra HG, Wang W, Tahara S, Yamamoto H, Chamie D, Kanaya T, Mehanna E, Takagi K, Nakamura S, Costa MA.

JACC Cardiovasc Interv. 2013 Oct;6(10):1035-45. doi: 10.1016/j.jcin.2013.05.015.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk